Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology

19 Dec 2016

Abstract excerpt

The growing use of next generation-sequencing to identify cancer-associated alterations as well as the increasing number of targeted drugs holds promise for better matching patients with cancer with effective therapies. The FoundationOne (F1; Foundation Medicine) test sequences clinical tumor samples to characterize the exons of 315 cancer-associated genes and introns from 28 genes involved in rearrangements. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27978570
DOI: 10.1001/jamaoncol.2016.4983

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in OncologyPMID 27978570Read ↗

Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.Semantic proximity Read ↗

A Canadian Guideline on the Use of Next-Generation Sequencing in OncologySemantic proximity Read ↗

Next-Generation Sequencing Concordance Analysis of Comprehensive Solid Tumor Profiling between a Centralized Specialty Laboratory and the Decentralized Personal Genome Diagnostics elio Tissue Complete Kitted Solution.Semantic proximity Read ↗

Next-generation DNA sequencing: implications for oncology care.Semantic proximity Read ↗

Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients.Semantic proximity Read ↗

Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experienceSemantic proximity Read ↗

Comparison of Comprehensive Genomic Profiling Testing “Ion Torrent Genexus Sequencer” with FoundationOneSemantic proximity Read ↗

Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.Semantic proximity Read ↗

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.Semantic proximity Read ↗

Comparison of Results from Two Commercially Available In-House Tissue-Based Comprehensive Genomic Profiling Solutions: Research Use Only AVENIO Tumor Tissue Comprehensive Genomic Profiling Kit and TruSight Oncology 500 Assay.Semantic proximity Read ↗

Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population.Semantic proximity Read ↗

Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.